New diagnostic criteria for neurocysticercosis: Reliability and validity
Open Access
- 13 August 2016
- journal article
- research article
- Published by Wiley in Annals of Neurology
- Vol. 80 (3) , 434-442
Abstract
Objective: The diagnosis of neurocysticercosis (NCC) remains problematic because of the heterogeneity of its clinical, immunological, and imaging characteristics. Our aim was to develop and assess a new set of diagnostic criteria for NCC, which might allow for the accurate detection of, and differentiation between, parenchymal and extraparenchymal disease.Methods: A group of Latin American NCC experts developed by consensus a new set of diagnostic criteria for NCC. A multicenter, retrospective study was then conducted to validate it. The reference standard for diagnosis of active NCC was the disappearance or reduction of cysts after anthelmintic treatment. In total, three pairs of independent neurologists blinded to the diagnosis evaluated 93 cases (with NCC) and 93 controls (without NCC) using the new diagnostic criteria. Mixed‐effects logistic regression models were used to estimate sensitivity and specificity.Results: Inter‐rater reliability (kappa) of diagnosis among evaluators was 0.60. For diagnosis of NCC versus no NCC, the new criteria had a sensitivity of 93.2% and specificity of 81.4%. For parenchymal NCC, the new criteria had a sensitivity of 89.8% and specificity of 80.7% and for extraparenchymal NCC, the new criteria had a sensitivity of 65.9% and specificity of 94.9%.Interpretation: These criteria have acceptable reliability and validity and could be a new tool for clinicians and researchers. An advantage of the new criteria is that they consider parasite location (ie, parenchymal or extraparenchymal), which is an important factor determining the clinical, immunological, and radiological presentation of the disease, and importantly, its treatment and prognosis. Ann Neurol 2016;80:434–442Keywords
Funding Information
- “Programa Iberoamericano de Ciencia y Tecnología para el Desarrollo”
- Department of Health's NIHR Biomedical Research Centres
- Dr. Marvin Weil Epilepsy Research Fund
- UK Epilepsy Society
This publication has 34 references indexed in Scilit:
- Added Value of Antigen ELISA in the Diagnosis of Neurocysticercosis in Resource Poor SettingsPLOS Neglected Tropical Diseases, 2012
- Standards for epidemiologic studies and surveillance of epilepsyEpilepsia, 2011
- Clinical Manifestations Associated with Neurocysticercosis: A Systematic ReviewPLOS Neglected Tropical Diseases, 2011
- Human Neurocysticercosis: Comparison of Different Diagnostic Tests Using Cerebrospinal FluidJournal of Clinical Microbiology, 2011
- A diagnostic and therapeutic scheme for a solitary cysticercus granulomaNeurology, 2010
- Severe Cysticercal Meningitis: Clinical and Imaging CharacteristicsThe American Journal of Tropical Medicine and Hygiene, 2010
- Effects of albendazole treatment on neurocysticercosis: a randomised controlled trialJournal of Neurology, Neurosurgery & Psychiatry, 2008
- Epileptic Seizures and Epilepsy: Definitions Proposed by the International League Against Epilepsy (ILAE) and the International Bureau for Epilepsy (IBE)Epilepsia, 2005
- Pre-treatment with corticosteroids and a single cycle of high dose albendazole for subarachnoidal cysticercosisJournal of Neurology, Neurosurgery & Psychiatry, 2004
- A monoclonal antibody-based ELISA for the detection of circulating excretory-secretory antigens in Taenia saginata cysticercosisInternational Journal for Parasitology, 1992